DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA Arzneimittel AG: STADA allows elaborated motion from Active Ownership
Fund as supplement to the Annual General Meeting 2016
13.05.2016 / 10:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Bad Vilbel, May 13, 2016 - STADA Arzneimittel AG has received an elaborated
motion from Active Ownership Fund SICAV-FIS SCS as a supplement to the
agenda of the STADA Annual General Meeting 2016. STADA conducted a review
of the motion and published it on its website.
On May 6, 2016, Active Ownership Fund had submitted an agenda amendment
motion to the Company, which the investor has now elaborated on.
Accordingly, the investor now proposes three instead of five new candidates
for election as shareholder representatives on the Supervisory Board.
Within the scope of its discretionary powers, the STADA Executive Board
decided to allow the agenda amendment motion in order to avoid the
substantial costs that would have been incurred in the case of legal action
from Active Ownership Fund to assert their request or the convening of an
extraordinary Annual General Meeting.
The Executive Board sees its obligations first and foremost in the well-
being of the company. For this reason, it would like to ensure a quick
decision in this matter. The Executive Board can thus concentrate on the
further implementation of the successful growth strategy in order to create
value for the company's shareholders.
It is now up to the shareholders to vote on the motion from Active
Ownership Fund at the Annual General Meeting on June 9, 2016.
STADA Chairman of the Supervisory Board Dr. Martin Abend commented on the
elaborated motion as follows: "In the interest of good corporate
governance, it is important to us that Supervisory Board members are
elected at the Annual General Meeting. Because we on the Supervisory Board
had already begun to look at questions related to the succession planning
process some time ago, a constructive dialog about the qualified
candidates, which I welcome, has taken place with Active Ownership Fund".
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de
Or visit us in the Internet at www.stada.com.
---------------------------------------------------------------------------
13.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart; Terminbörse EUREX
End of News DGAP News Service
---------------------------------------------------------------------------
463571 13.05.2016
DGAP-News: STADA Arzneimittel AG: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016
| Source: EQS Group AG